NAV

CUDC-907

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
CUDC-907
DrugBank Accession Number
DB11891
Background

CUDC-907 has been used in trials studying the treatment of Lymphoma, Solid Tumors, BREAST CANCER, Multiple Myeloma, and NUT Midline Carcinoma, among others.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 508.56
Monoisotopic: 508.164122459
Chemical Formula
C23H24N8O4S
Synonyms
Not Available
External IDs
  • CUDC907

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with CUDC-907.
AdenosineThe risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Adenosine.
AjmalineThe risk or severity of QTc prolongation can be increased when Ajmaline is combined with CUDC-907.
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with CUDC-907.
AlimemazineThe risk or severity of QTc prolongation can be increased when Alimemazine is combined with CUDC-907.
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with CUDC-907.
AmifampridineThe risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Amifampridine.
AmiodaroneThe risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Amiodarone.
AmisulprideThe risk or severity of QTc prolongation can be increased when Amisulpride is combined with CUDC-907.
AmitriptylineThe risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Amitriptyline.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as pyridinylpyrimidines. These are compounds containing a pyridinylpyrimidine skeleton, which consists of a pyridine linked (not fused) to a pyrimidine by a bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Pyridinylpyrimidines
Alternative Parents
Thienopyrimidines / Pyrimidinecarboxamides / 2,3,5-trisubstituted thiophenes / Dialkylarylamines / Alkyl aryl ethers / Aminopyrimidines and derivatives / Pyridines and derivatives / Morpholines / Imidolactams / Heteroaromatic compounds
show 6 more
Substituents
2,3,5-trisubstituted thiophene / Alkyl aryl ether / Amine / Aminopyrimidine / Aromatic heteropolycyclic compound / Azacycle / Carboxylic acid derivative / Dialkyl ether / Dialkylarylamine / Ether
show 18 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
3S9RX35S5X
CAS number
1339928-25-4
InChI Key
JOWXJLIFIIOYMS-UHFFFAOYSA-N
InChI
InChI=1S/C23H24N8O4S/c1-30(23-25-11-15(12-26-23)22(32)29-33)13-16-9-17-19(36-16)21(31-5-7-35-8-6-31)28-20(27-17)14-3-4-18(34-2)24-10-14/h3-4,9-12,33H,5-8,13H2,1-2H3,(H,29,32)
IUPAC Name
N-hydroxy-2-({[2-(6-methoxypyridin-3-yl)-4-(morpholin-4-yl)thieno[3,2-d]pyrimidin-6-yl]methyl}(methyl)amino)pyrimidine-5-carboxamide
SMILES
COC1=CC=C(C=N1)C1=NC(N2CCOCC2)=C2SC(CN(C)C3=NC=C(C=N3)C(=O)NO)=CC2=N1

References

General References
Not Available
PubChem Compound
54575456
PubChem Substance
347828226
ChemSpider
29314960
BindingDB
50188961
ChEMBL
CHEMBL3622533
ZINC
ZINC000073488511
Wikipedia
Phosphoinositide_3-kinase_inhibitor

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentRelapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations1
2TerminatedTreatmentDifferentiated Thyroid Cancer (DTC) / Neoplasms, Thyroid / Poorly Differentiated and Undifferentiated Thyroid Cancer1
1CompletedTreatmentDouble-expressor Lymphoma (DEL) / Double-hit Lymphoma (DHL) / High Grade B-cell Lymphoma (HGBCL) / Malignant Lymphomas / Refractory Diffuse Large B Cell Lymphoma (DLBCL) / Refractory Lymphomas / Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) / Relapsed and/or Refractory Lymphoma / Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL) / Relapsed Lymphomas / Triple-hit Lymphoma (THL)1
1CompletedTreatmentHigh Grade Serous Ovarian Cancer / NUT Midline Carcinoma (NMC) / Solid Tumors / Triple Negative Breast Cancer1
1RecruitingTreatmentMalignant Lymphomas / Neoplasms, Brain / Neuroblastoma (NB) / Solid Tumors1
0RecruitingTreatmentDiffuse Intrinsic Pontine Gliomas (DIPG) / Recurrent Anaplastic Astrocytoma / Recurrent Glioblastoma / Recurrent Malignant Gliomas / Recurrent Medulloblastoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0153 mg/mLALOGPS
logP2.59ALOGPS
logP2.78ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)9.24ChemAxon
pKa (Strongest Basic)3.36ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count11ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area138.72 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity145.82 m3·mol-1ChemAxon
Polarizability53.01 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at October 20, 2016 20:57 / Updated at June 12, 2020 16:53